{"id":1432,"date":"2024-02-22T20:09:25","date_gmt":"2024-02-22T20:09:25","guid":{"rendered":"https:\/\/stoxpo.com\/?p=1432"},"modified":"2024-02-22T20:09:25","modified_gmt":"2024-02-22T20:09:25","slug":"ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\/","title":{"rendered":"Ocular Therapeutix Announces Private Placement to Bolster Clinical Development Initiatives"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Ocular Therapeutix, Inc. (OCUL), a pioneering biopharmaceutical company dedicated to advancing vision-related therapies, has disclosed its strategic move to enhance its research and development endeavors. The company has entered into a securities purchase agreement with institutional accredited investors, aiming to secure approximately $325.0 million in aggregate gross proceeds through a private placement.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This placement, attracting both new and existing investors such as Venrock Healthcare Capital Partners and Perceptive Advisors, underscores confidence in Ocular Therapeutix&#8217;s innovative vision care solutions. The private placement involves the issuance of 32,413,560 shares of common stock at $7.52 per share, alongside pre-funded warrants to purchase up to 10,805,957 shares of common stock.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Expected to close on February 26, 2024, pending customary closing conditions, BofA Securities acts as the sole placement agent for the transaction. The infusion of funds will fuel the accelerated clinical development of AXPAXLI\u2122, particularly advancing its pivotal Phase 3 clinical trials for treating wet AMD.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These proceeds will also support Ocular Therapeutix&#8217;s broader clinical programs and bolster its financial position for future growth initiatives. With a clear focus on innovation and clinical advancement, Ocular Therapeutix remains steadfast in its mission to revolutionize eye care treatments and improve patients&#8217; quality of life.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ocular Therapeutix, Inc. (OCUL), a pioneering biopharmaceutical company dedicated to advancing vision-related therapies, has disclosed its strategic move to enhance its research and development endeavors. The company has entered into a securities purchase agreement with institutional accredited investors, aiming to secure approximately $325.0 million in aggregate gross proceeds through a private placement. This placement, attracting [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1431,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"1","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"1","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]},"footnotes":""},"categories":[308,359],"tags":[],"coauthors":[453],"class_list":["post-1432","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","category-small-cap"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ocular Therapeutix Announces Private Placement to Bolster Clinical Development Initiatives - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocular Therapeutix Announces Private Placement to Bolster Clinical Development Initiatives - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Ocular Therapeutix, Inc. (OCUL), a pioneering biopharmaceutical company dedicated to advancing vision-related therapies, has disclosed its strategic move to enhance its research and development endeavors. The company has entered into a securities purchase agreement with institutional accredited investors, aiming to secure approximately $325.0 million in aggregate gross proceeds through a private placement. This placement, attracting [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-22T20:09:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-ksenia-chernaya-5765830-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1709\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Liliana Vida\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Liliana Vida\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\\\/\"},\"author\":{\"name\":\"Liliana Vida\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\"},\"headline\":\"Ocular Therapeutix Announces Private Placement to Bolster Clinical Development Initiatives\",\"datePublished\":\"2024-02-22T20:09:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\\\/\"},\"wordCount\":203,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-ksenia-chernaya-5765830-scaled.jpg\",\"articleSection\":[\"Biotechnology\",\"Small-Cap\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\\\/\",\"name\":\"Ocular Therapeutix Announces Private Placement to Bolster Clinical Development Initiatives - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-ksenia-chernaya-5765830-scaled.jpg\",\"datePublished\":\"2024-02-22T20:09:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-ksenia-chernaya-5765830-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-ksenia-chernaya-5765830-scaled.jpg\",\"width\":2560,\"height\":1709,\"caption\":\"opthalmology\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/02\\\/22\\\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocular Therapeutix Announces Private Placement to Bolster Clinical Development Initiatives\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\",\"name\":\"Liliana Vida\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"caption\":\"Liliana Vida\"},\"description\":\"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/stoxpo-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocular Therapeutix Announces Private Placement to Bolster Clinical Development Initiatives - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\/","og_locale":"en_US","og_type":"article","og_title":"Ocular Therapeutix Announces Private Placement to Bolster Clinical Development Initiatives - Stoxpo","og_description":"Ocular Therapeutix, Inc. (OCUL), a pioneering biopharmaceutical company dedicated to advancing vision-related therapies, has disclosed its strategic move to enhance its research and development endeavors. The company has entered into a securities purchase agreement with institutional accredited investors, aiming to secure approximately $325.0 million in aggregate gross proceeds through a private placement. This placement, attracting [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\/","og_site_name":"Stoxpo","article_published_time":"2024-02-22T20:09:25+00:00","og_image":[{"width":2560,"height":1709,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-ksenia-chernaya-5765830-scaled.jpg","type":"image\/jpeg"}],"author":"Liliana Vida","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Liliana Vida","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\/"},"author":{"name":"Liliana Vida","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1"},"headline":"Ocular Therapeutix Announces Private Placement to Bolster Clinical Development Initiatives","datePublished":"2024-02-22T20:09:25+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\/"},"wordCount":203,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-ksenia-chernaya-5765830-scaled.jpg","articleSection":["Biotechnology","Small-Cap"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\/","url":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\/","name":"Ocular Therapeutix Announces Private Placement to Bolster Clinical Development Initiatives - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-ksenia-chernaya-5765830-scaled.jpg","datePublished":"2024-02-22T20:09:25+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-ksenia-chernaya-5765830-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-ksenia-chernaya-5765830-scaled.jpg","width":2560,"height":1709,"caption":"opthalmology"},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2024\/02\/22\/ocular-therapeutix-announces-private-placement-to-bolster-clinical-development-initiatives\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"Ocular Therapeutix Announces Private Placement to Bolster Clinical Development Initiatives"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1","name":"Liliana Vida","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6","url":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","caption":"Liliana Vida"},"description":"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/stoxpo-com\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=1432"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1432\/revisions"}],"predecessor-version":[{"id":1433,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1432\/revisions\/1433"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1431"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=1432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=1432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=1432"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=1432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}